Elanco Animal Health. has filed a patent for soft chewable dosage forms for veterinary use. The composition includes an active ingredient and a carbonate compound acting as a disintegrant. GlobalData’s report on Elanco Animal Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Elanco Animal Health, NSAID cancer drugs was a key innovation area identified from patents. Elanco Animal Health's grant share as of September 2023 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Chewable veterinary composition with active ingredient and carbonate compound
A recently filed patent (Publication Number: US20230277448A1) describes a chewable veterinary composition that includes an active pharmaceutical ingredient and a carbonate compound. The carbonate compound mentioned in the patent is specifically sodium bicarbonate. The composition can contain sodium bicarbonate in varying concentrations, ranging from 0.5% to 40.0% (wt/wt) or 1.0% to 4.0% (wt/wt).
The active pharmaceutical ingredient in the composition can belong to the isooxazoline class parasiticide, such as lotilaner, fluralaner, afoxalaner, or sarolaner. Alternatively, it can be a macrocyclic lactone class parasiticide, like moxidectin or milbemycin oxime. Other active ingredients mentioned in the patent include praziquantel, pyrantel pamoate, and monepantel.
The patent also specifies the average particle size of the carbonate compound, preferably sodium bicarbonate, which can range from 10-250 µm, 20-200 µm, 30-150 µm, or 40-100 µm. However, the preferred range is 30-150 µm or 40-100 µm.
In one embodiment, the composition includes praziquantel as a coated pellet. The pellet substrate can be made of microcrystalline cellulose, and the coating can consist of praziquantel and a physiologically acceptable polymer, optionally dimethylaminoethyl methacrylate-copolymer.
Another claim in the patent describes a chewable veterinary composition that includes specific concentrations of various active ingredients. This composition contains 0.5% to 25% (wt/wt) of an isoxazoline (e.g., lotilaner, sarolaner, fluralaner, or afoxolaner), 0.005% to 1% (wt/wt) moxidectin, 1% to 10% (wt/wt) praziquantel, 5% to 30% (wt/wt) pyrantel pamoate, and optionally 1.0% to 10.0% (wt/wt), more optionally 1.0% to 5.0% (wt/wt), and even more optionally 4.0% (wt/wt) sodium bicarbonate.
Overall, this patent describes a chewable veterinary composition that includes specific active pharmaceutical ingredients and a carbonate compound, particularly sodium bicarbonate. The patent also provides details on the concentration ranges and particle sizes of the ingredients, as well as specific embodiments involving coated pellets.
To know more about GlobalData’s detailed insights on Elanco Animal Health, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
